Clinical Trial Update: Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing maribavir to oral ganciclovir for CMV disease prevention in liver transplant recipients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections
• Liver Transplant Recipients

Drugs mentioned

• GANCICLOVIR (GANCICLOVIR SODIUM)
• Maribavir (maribavir)

Snippet

Sponsor: Shire | Conditions: Cytomegalovirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2015-06-04